Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 3Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Multiple Myeloma 1

Interventions

Dexamethasone 70Cyclophosphamide 44Bortezomib 41Lenalidomide 25Melphalan 24Thalidomide 19pomalidomide 17daratumumab 14fludarabine 13carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6isatuximab 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Calcium Dobesilate 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4liposomal doxorubicin 3ixazomib 3dexamethasone acetate 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Influenza Vaccines × Plasma cell × Clear all
NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡